Assembly Biosciences, Inc.(ASMB)

$36.60—Stale · unknown old

Chart

Assembly Biosciences, Inc.(ASMB)

NASDAQ • Last print unknown ago

$36.60—Stale · unknown old

Chart Studio

ASMB(ASMB)

ASMB

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.66

Nov 9, 2026 · Reports after close

Revenue Estimate

$9M

Analyst Sentiment

Wall St. Consensus

Buy

11 analysts·Moderate coverage

Score

6 Buy (55%)5 Hold (45%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

655%

Hold

545%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$50.00

+36.6%

Consensus

$52.00

+42.1%

Bull

$53.00

+44.8%

12-Month Target Range11 analysts

$50.00$52.00$53.00

Current $36.60Consensus

Current Price

$36.60

Upside to Consensus

$15.40

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-32.21%

EPS—

FY2028

Rev+52.33%

EPS—

FY2029

Rev-57.25%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$63M	$43M	$66M	$28M	$124M
Low	$20M	$23M	$34M	$15M	$65M
High	$106M	$66M	$101M	$43M	$190M
EBITDA Avg	$-6M	$-56M	$-46M	$-32M	$-12M
Low	$-10M	$-56M	$-54M	$-56M	$-24M
High	$-1M	$-11M	$20M	$-10M	$-1M
EBIT Avg	$-7M	$-58M	$-49M	$-35M	$-17M
Low	$-12M	$-58M	$-57M	$-59M	$-29M
High	$-3M	$-13M	$17M	$-13M	$-7M
Net Income Avg	$-7M	$-58M	$-49M	$-35M	$-17M
Low	$-12M	$-58M	$-57M	$-59M	$-29M
High	$-3M	$-13M	$14M	$-13M	$-7M
EPS Avg	$-0.61	$-3.06	$-1.96	$-3.10	$-1.53
Low	$-1.03	$-5.20	$-5.05	$-5.27	$-2.60
High	$-0.23	$-1.16	$1.21	$-1.18	$-0.58
Analysts (Rev / EPS)	4 / 3	3 / 3	4 / 3	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$9M	$43M	$11M	$2M	$2M	$31M
Low	$9M	$43M	$11M	$2M	$2M	$31M
High	$9M	$43M	$11M	$2M	$2M	$31M
EBITDA Avg	$-12M	$12M	$-11M	$-19M	$-20M	$5M
Low	$-12M	$12M	$-11M	$-19M	$-20M	$5M
High	$-12M	$12M	$-11M	$-19M	$-20M	$5M
EBIT Avg	$-12M	$12M	$-11M	$-20M	$-20M	$5M
Low	$-12M	$12M	$-11M	$-20M	$-20M	$5M
High	$-12M	$12M	$-11M	$-20M	$-20M	$5M
Net Income Avg	$-12M	$9M	$-11M	$-20M	$-20M	$4M
Low	$-12M	$9M	$-11M	$-20M	$-20M	$4M
High	$-12M	$9M	$-11M	$-20M	$-20M	$4M
EPS Avg	$-0.66	$0.48	$-0.60	$-1.05	$-1.05	$0.20
Low	$-0.66	$0.48	$-0.60	$-1.05	$-1.05	$0.20
High	$-0.66	$0.48	$-0.60	$-1.05	$-1.05	$0.20
Analysts (Rev / EPS)	3 / 2	3 / 2	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Sep 1, 2026Mizuho Securities

Assembly Biosciences price target raised to $53 from $45 at Mizuho

Target:$53.00

+57.6%from $33.63

Sep 1, 2026UBS

UBS Starts Assembly Biosciences (ASMB) at Buy

Target:$52.00

+54.6%from $33.63

Aug 18, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Assembly Biosciences (ASMB)

Target:$50.00

+66.6%from $30.01

Jun 15, 2026Mizuho Securities

Assembly Biosciences price target raised to $45 from $40 at Mizuho

Target:$45.00

+96.0%from $22.96

Nov 20, 2025Mizuho Securities

Assembly Biosciences price target raised to $40 from $29 at Mizuho

Target:$40.00

+2.6%from $39.00

Sep 24, 2025JMP Securities

Assembly Biosciences initiated with an Outperform at Citizens JMP

Target:$38.00

+46.7%from $25.90

Sep 24, 2024Mizuho Securities

Mizuho Reiterates Outperform Rating on Assembly Biosciences (ASMB)

Target:$36.00

+121.4%from $16.26

Sep 20, 2024Jefferies

Jefferies Upgrades Assembly Biosciences (ASMB) to Buy

Target:$35.00

+89.2%from $18.50

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance